指南与共识白血病

慢性髓性白血病分子监测标准化:欧洲治疗与结局研究的结果与建议

Standardization of molecular monitoring of CML: results and recommendations from the European treatment and outcome study.
指南 / 共识 · Leukemia · 2022-05-25

2016至2021年,欧洲慢性髓性白血病治疗与结局研究(EUTOS)探索使用可溯源至世界卫生组织一级参考材料的二级冻干细胞BCR::ABL1参考品,以标准化和验证本地实验室检测。EUTOS参考实验室(n=50)中,ABL1和GUSB的转换因子(CF)验证为最佳或满意的比例分别从67.5%升至97.6%、从36.4%升至91.7%,98%的实验室能在多数样本中检出MR4.5。CF未经验证的实验室BCR::ABL1IS变异系数更高,部分实验室空白限大于零,可能影响深度分子学反应(DMR)的准确报告。

要点

  • 二级参考品可有效获得和验证CF,效果等同于样本交换。
  • EUTOS参考实验室ABL1的CF验证最佳或满意比例从67.5%升至97.6%。
  • GUSB的CF验证最佳或满意比例从36.4%升至91.7%。

核心结论

  • 二级参考品可有效获得和验证转换因子,效果等同于样本交换,并可用于监测其他质量保证方面。

研究设计与样本

  • 2016至2021年欧洲慢性髓性白血病治疗与结局研究(EUTOS)探索使用二级冻干细胞BCR::ABL1参考品标准化和验证本地实验室检测。
  • 参考品用于分配和验证国际标准转换因子并评估实验室检测深度分子学反应的能力,同时探索内部质量控制。

主要发现

  • EUTOS参考实验室(n=50)中ABL1的CF验证为最佳或满意的比例从67.5%升至97.6%。
  • GUSB的CF验证为最佳或满意的比例从36.4%升至91.7%。
  • 98%的实验室能在多数样本中检出MR4.5。
  • CF未经验证的实验室BCR::ABL1IS变异系数更高。
  • 部分实验室空白限大于零,可能影响深度分子学反应的准确报告。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Standardized monitoring of BCR::ABL1 mRNA levels is essential for the management of chronic myeloid leukemia (CML) patients. From 2016 to 2021 the European Treatment and Outcome Study for CML (EUTOS) explored the use of secondary, lyophilized cell-based BCR::ABL1 reference panels traceable to the World Health Organization primary reference material to standardize and validate local laboratory tests. Panels were used to assign and validate conversion factors (CFs) to the International Scale and assess the ability of laboratories to assess deep molecular response (DMR). The study also explored aspects of internal quality control. The percentage of EUTOS reference laboratories (n = 50) with CFs validated as optimal or satisfactory increased from 67.5% to 97.6% and 36.4% to 91.7% for ABL1 and GUSB, respectively, during the study period and 98% of laboratories were able to detect MR4.5 in most samples. Laboratories with unvalidated CFs had a higher coefficient of variation for BCR::ABL1IS and some laboratories had a limit of blank greater than zero which could affect the accurate reporting of DMR. Our study indicates that secondary reference panels can be used effectively to obtain and validate CFs in a manner equivalent to sample exchange and can also be used to monitor additional aspects of quality assurance.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. White HE, Salmon M, Albano F, et al. Standardization of molecular monitoring of CML: results and recommendations from the European treatment and outcome study. Leukemia. 2022. PMID: 35614319. doi:10.1038/s41375-022-01607-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。